NEW YORK (GenomeWeb News) – Clinical research organization Covance said after the close of the market on Wednesday that it will acquire Merck's Seattle-based gene expression laboratory.

Although the Princeton, NJ-based firm did not disclose the price of the acquisition, it said that Merck had committed to a five-year genomic analysis services contract worth $145 million as part of the deal. The lab performs genotyping, gene sequencing, and gene expression profiling services. The firms did not provide revenue figures for the lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.